Asahi Ka­sei ac­quires Biono­va and its shiny new Cal­i­for­nia site

Just months af­ter it opened a new GMP man­u­fac­tur­ing site, the US-based bio­phar­ma CD­MO Biono­va Sci­en­tif­ic has been ac­quired by Asahi Ka­sei Med­ical.

The com­pa­ny an­nounced the ac­qui­si­tion Mon­day evening, how­ev­er, the deal was fi­nal­ized April 14, the com­pa­ny said.

Biono­va spe­cial­izes in com­plex next-gen­er­a­tion an­ti­body drugs, which can be dif­fi­cult to man­u­fac­ture. It launched the full-ser­vice com­mer­cial-ready GMP man­u­fac­tur­ing site in Fre­mont, CA, just north of San Jose, in Oc­to­ber. With the ac­qui­si­tion, Asahi Ka­sei will get near­ly 80,000-square-feet of CD­MO fa­cil­i­ties and a num­ber of state-of-the-art in­stru­ments and equip­ment, in­clud­ing sin­gle-use biore­ac­tors. The ac­qui­si­tion will al­so al­low Asahi Ka­sei to add a CD­MO to its bio­process busi­ness.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER